Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic ...

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novartis ...

This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape.Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - ...

Priced at $373,000 per patient, Gilead’s Yescarta (axicabtagene ciloleucel) has just been approved by the FDA for adults with relapsed or refractory large B-cell lymphoma after two or more lines ...

Early in 2024, we reported on the FDA's call for new boxed warnings on the labeling of all approved chimeric antigen receptor ...

The division, which will expand on the already-existing Released Soldiers’ Division and Fund, will include a dedicated branch for reservists’ welfare and be led by Col. (res.) Eyal Hans ...

A team at the University of Calgary is making scientific advances in understanding plant adaptation, which could ultimately be used to find ways to make agricultural crops more resilient to heat ...

The U.S. Congress formally certified Republican President-elect Donald Trump's November election victory over Democratic Vice President Kamala Harris, clearing the way for him to be sworn in on ...